7.81  0.52 (7.13%)		09-14 16:00
Open: 7.4 High: 7.81 Volume: 96,446		Pre. Close: 7.29 Low: 7.27 Market Cap: 147(M)

Short term
Mid term
Targets	6-month :	9.48	1-year :	10.6
Resists	First :	8.12	Second :	9.07
Pivot price	7.71
Supports	First :	6.57	Second :	5.46
MAs	MA(5) :	7.4	MA(20) :	7.8
	MA(100) :	6.33	MA(250) :	10.18
MACD	MACD :	0	Signal :	0.2
%K %D	K(14,3) :	38	D(3) :	21.7
RSI	RSI(14): 55.6
52-week	High :	22.25	Low :	4.53

Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.
[ OPRX ] has closed below upper band by 41.8%. Bollinger Bands are 30% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.

If tomorrow:	Open lower	Open higher
High:	7.82 - 7.85	7.85 - 7.89
Low:	7.2 - 7.23	7.23 - 7.26
Close:	7.76 - 7.81	7.81 - 7.87

OptimizeRx Corp. is digital health company, engaged in the provision of digital health messaging via electronic health records, which serve as a direct channel for pharmaceutical companies to communicate with healthcare providers. It offers electronic health record (EHR) workflow solutions which include financial messaging, patient education, and brand messaging and brand support. The company was founded by David A. Harrell in 2006 and is headquartered in Waltham, MA.

Mon, 14 Sep 2026
One prompt now builds patient and doctor audiences. OptimizeRx expanded the tool. - Stock Titan

Tue, 08 Sep 2026
A 10th annual growth conference is set for New York, with OptimizeRx taking part. - Stock Titan

Sat, 05 Sep 2026
Optimizerx Stock Price Forecast. Should You Buy OPRX? - StockInvest.us

Wed, 02 Sep 2026
OptimizeRx (OPRX) insider stock withheld for taxes - Stock Titan

Wed, 02 Sep 2026
OptimizeRx Appoints Former Johnson & Johnson Executive Troy Sarich as Company Advisor - Quiver Quantitative

Wed, 12 Aug 2026
OptimizeRx Corp. (OPRX) Q2 Earnings and Revenues Top Estimates - finance.yahoo.com

Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.	Outperform
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).	Underperform
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.	Outperform
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.	Outperform
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.	Neutral
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.	Neutral

Exchange: NASDAQ
Sector: Healthcare
Industry: Medical - Healthcare Information Services
Shares Out	19 (M)
Shares Float	14 (M)
Held by Insiders	13.8 (%)
Held by Institutions	69.6 (%)
Shares Short	1,150 (K)
Shares Short P.Month	1,460 (K)

EPS	0.25
EPS Est Next Qtrly	0
EPS Est This Year	0
EPS Est Next Year	0
Book Value (p.s.)	6.96
Profit Margin	4.6 %
Operating Margin	-0.5 %
Return on Assets (ttm)	4.2 %
Return on Equity (ttm)	3.6 %
Qtrly Rev. Growth	-29.8 %
Gross Profit (p.s.)	3.83
Sales Per Share	5.23
EBITDA (p.s.)	0.82
Qtrly Earnings Growth	0 %
Operating Cash Flow	18 (M)
Levered Free Cash Flow	16 (M)

PE Ratio	31.23
PEG Ratio	1.6
Price to Book value	1.12
Price to Sales	1.49
Price to Cash Flow	7.98

Dividend	0
Forward Dividend	0
Dividend Yield	0%
Dividend Pay Date	Invalid DateTime.
Ex-Dividend Date	Invalid DateTime.